ClinicalTrials.gg
CompletedNCT07789262ARF-PRFUpdated Aug 27, 2026

Autogenous Dentin Graft for Alveolar Ridge Preservatio

An interventional study of Autogenous Dentin Graft and Platelet-Rich Fibrin (PRF) in Tooth Extraction and Alveolar Bone Loss, sponsored by Ankara Yildirim Beyazıt University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Ankara Yildirim Beyazıt University · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 2 years 8 months after the study started (first participant enrolled Dec 2023, registered Aug 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-14

Among 33 studies in Alveolar Bone Loss with a site in Turkey — 8 open to participants now, 10 under way, none of them phase 3. Alveolar Bone Loss · Turkey.

Enrollment
19th of 20
9 · median 30
Started
2023
with 5 others
No phase
18 of 33
4 open now
Registered
30th of 33
by date
Lead sponsor
1 of 33
Ankara Yildirim Beyazıt University

Among the 33 studies in Alveolar Bone Loss with a site in Turkey, this one is the 19th largest by enrollment of the 20 interventional ones that give a count, is one of 6 that started in 2023, is one of 18 with no phase, and was the 30th registered.

Alveolar Bone Loss

319 studies on the registry are indexed under Alveolar Bone Loss; 79 are open to participants now.

Browse Alveolar Bone Loss studies →

Open to participants now

8 of the 33 studies in Alveolar Bone Loss with a site in Turkey are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 47 Alveolar Bone Loss studies recruiting now, 19 (40%) set no upper age limit and 22 (47%) stop at 75 or younger; 4 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Alveolar Bone Loss with a site in Turkey, or all of them as a file.
02

Study summary

When a tooth is extracted, the bone around the empty socket naturally shrinks over time, which can make it difficult to place a dental implant later without additional bone-building procedures. This study investigated whether grafting the socket with the patient's own extracted tooth material, processed into a graft (autogenous dentin graft), can help preserve this bone. The study also examined whether adding platelet-rich fibrin (PRF), a concentrate prepared from the patient's own blood that is rich in healing factors, could further improve outcomes. A total of 56 extraction sockets were randomly assigned to one of four treatment approaches: no grafting (natural healing), dentin graft alone, dentin graft combined with PRF, or a freeze-dried bone allograft, which is a commonly used bone substitute for comparison. Four months after treatment, small bone samples were taken from each site at the time of dental implant placement and examined under the microscope to measure how much new bone had formed, along with other markers of healing such as blood vessel formation and a bone-growth protein called BMP-2. The results showed that sockets treated with dentin graft healed at least as well as those treated with the standard bone substitute, and that combining dentin graft with PRF produced the best healing results of all groups tested. These findings suggest that a patient's own extracted tooth, which would otherwise be discarded, may serve as an effective and low-cost graft material for preserving bone after tooth extraction, particularly when combined with PRF.

Read the detailed description

Following tooth extraction, the alveolar ridge undergoes progressive dimensional changes, primarily due to bundle bone resorption, which may compromise the volume and quality of bone available for future implant placement. Alveolar ridge preservation (ARP) procedures aim to minimize this resorption through the use of various grafting materials.

This prospective, randomized, controlled clinical trial was conducted at the Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Ankara Yıldırım Beyazıt University. Eligible participants were systemically healthy individuals aged ≥18 years (ASA I-II) who required extraction of a radiographically non-infected tooth. Patients with acute infection at the extraction site, advanced systemic disease, use of medications affecting bone metabolism, smoking or alcohol consumption, or anticipated non-compliance with follow-up visits were excluded.

A total of 56 extraction sockets from nine patients (six women and three men; age range, 24-55 years) were randomly allocated into four groups: Control (spontaneous healing without grafting, n = 13), Dentin (grafted with autogenous dentin particles, n = 14), Dentin + PRF (grafted with autogenous dentin combined with leukocyte- and platelet-rich fibrin, n = 15), and FDBA (grafted with freeze-dried bone allograft, n = 14). All surgical procedures were performed by the same operator to eliminate inter-operator variability.

The sample size was calculated using G*Power version 3.1.9.6 (Universität Kiel, Germany), based on a repeated-measures ANOVA design, an effect size of 0.20, a statistical power of 80%, and an alpha level of 0.05. The analysis indicated that a minimum of 52 extraction sockets (13 per group) was required.

Autogenous dentin grafts were prepared immediately after extraction according to the method described by Binderman et al. Soft-tissue remnants, enamel, and cementum were removed from the extracted teeth using a tungsten carbide bur under water cooling. The cleaned teeth were processed using a Smart Dentin Grinder (KometaBio, Israel) to obtain particulate graft material with a particle size of 300-1200 µm. The particles were subsequently disinfected for 10 min in a solution containing 20% ethanol and 0.5 M NaOH and rinsed with a buffered saline solution to neutralize the pH before graft placement.

For the Dentin + PRF group, platelet-rich fibrin was prepared from 10 mL of venous blood collected in sterile tubes without anticoagulant and centrifuged at approximately 2700-3000 rpm for 10-12 min according to the Choukroun protocol. The resulting PRF clot was compressed into a membrane, cut into small fragments, and homogeneously mixed with the dentin particles before placement into the extraction sockets.

Full-thickness mucoperiosteal flaps were elevated as required in the Dentin and Dentin + PRF groups, and the graft materials were adapted to ensure close contact with the socket walls. In the FDBA group, the commercially available allograft was placed with minimal or no flap elevation. In the Control group, the extraction sockets were allowed to heal spontaneously through blood clot formation without graft placement or flap surgery. The flaps were closed using 3-0 silk sutures. In selected cases in which primary closure could not be achieved, a free gingival graft was used as a "socket seal." Postoperative care consisted of a standard antibiotic regimen (amoxicillin/clavulanic acid, 1000 mg twice daily for 7 days), an NSAID analgesic, and a chlorhexidine/benzydamine mouth rinse. Sutures were removed on postoperative day 10, and patients were followed clinically at monthly intervals.

Four months after grafting, at the time of dental implant placement, cylindrical bone-core biopsies were obtained from the treated alveolar ridge using a trephine bur. Specimens were fixed in 10% neutral buffered formalin, decalcified in 10% formic acid, and processed for routine histological embedding. Sections (5 µm thick) were stained with hematoxylin and eosin for histomorphometric evaluation of newly formed bone, connective tissue, vascularization, and residual graft particles.

Immunohistochemical staining for bone morphogenetic protein-2 (BMP-2) was performed following antigen retrieval. BMP-2 expression was quantified using a semi-quantitative HSCORE method combining staining intensity (0-3) and the percentage of positively stained cells. Five randomly selected fields per section were evaluated at ×40 magnification independently by two blinded observers.

Statistical analyses were performed using IBM SPSS Statistics version 21. The normality of continuous variables was assessed using the Shapiro-Wilk test. Normally distributed variables were analyzed using one-way ANOVA followed by Bonferroni post hoc comparisons, whereas non-normally distributed variables were analyzed using the Kruskal-Wallis test followed by Bonferroni-corrected Mann-Whitney U tests for pairwise comparisons. A p-value ≤ 0.05 was considered statistically significant.

03

Conditions studied

  • Tooth Extraction
  • Alveolar Bone Loss

Browse trials for

Keywords

  • Alveolar ridge preservation
  • Autogenous dentin graft
  • Platelet-rich fibrin
  • Extraction socket
  • Bone regeneration
  • BMP-2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Systemically healthy individuals ()
  • Age 18 years or older
  • Presence of a tooth requiring extraction, radiographically confirmed to be non-infected

Exclusion criteria

Exclusion Criteria:

  • Presence of acute infection at the extraction site
  • Advanced systemic disease
  • Use of medications known to affect bone metabolism
  • Current smoking or alcohol use
  • Anticipated non-compliance with scheduled follow-up visits
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
9 participants (actual)

Study arms

  • No intervention
    Control

    Extraction sockets were left to heal spontaneously without any graft material, based on natural blood clot formation, with no flap surgery performed.

  • Experimental
    Dentin

    Extraction sockets were grafted with autogenous dentin particles obtained from the patient's own extracted tooth, processed using the Smart Dentin Grinder device.

    Biological: Autogenous Dentin Graft

  • Experimental
    Dentin + PRF

    Extraction sockets were grafted with autogenous dentin particles combined with platelet-rich fibrin (PRF) prepared from the patient's own venous blood.

    Biological: Autogenous Dentin Graft · Biological: Platelet-Rich Fibrin (PRF)

  • Active comparator
    FDBA

    Extraction sockets were grafted with a commercial freeze-dried bone allograft (FDBA), used as a standard comparator graft material.

    Biological: Freeze-Dried Bone Allograft (FDBA)

Interventions

  • BiologicalAutogenous Dentin Graft

    Particulate graft material (300-1200 µm) obtained by processing the patient's own extracted tooth using the Smart Dentin Grinder device (KometaBio, Israel), placed into the extraction socket.

  • Autogenous dentin particles combined with platelet-rich fibrin, prepared by centrifugation of the patient's own venous blood (2700-3000 rpm, 10-12 minutes), placed into the extraction socket.

  • BiologicalFreeze-Dried Bone Allograft (FDBA)

    Commercial freeze-dried bone allograft placed into the extraction socket as a comparator graft material.

06

What researchers measure

Primary outcomes

  1. Percentage of Newly Formed Bone

    Histomorphometric quantification of the percentage of newly formed bone within the grafted extraction socket, assessed on hematoxylin and eosin-stained sections of bone core biopsies obtained at the time of implant placement.

    Time frame: 4 months after grafting

  2. Percentage of Connective Tissue Formation

    Histomorphometric quantification of the percentage of connective tissue within the bone core biopsy specimens.

    Time frame: 4 months after grafting

  3. Vascularization

    Histomorphometric assessment of new vessel formation within the bone core biopsy specimens.

    Time frame: 4 months after grafting

  4. BMP-2 Immunoexpression (HSCORE)

    Semi-quantitative immunohistochemical assessment of bone morphogenetic protein-2 (BMP-2) expression, calculated using the HSCORE method combining staining intensity and percentage of positive cells.

    Time frame: 4 months after grafting

07

Study locations

1 site
  • Ankara Yıldırım Beyazıt University, Faculty of Dentistry
    Ankara, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared, as this was not specified in the study protocol approved by the institutional ethics committee, and participant consent did not include provisions for external data sharing.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in Apr 2024, 4 months.

Of 168 non-industry interventional studies with no phase under Alveolar Bone Loss, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 30. This study's 4 months is below that.

Counting every sponsor, half of 168 studies reached it within 18 months; a quarter within 11 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2026
First posted
Aug 27, 2026
StartActual
Dec 15, 2023
Primary completionActual
Apr 15, 2024
CompletionActual
Dec 8, 2025
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07789262
Responsible party
Kevser SANCAK (Associate Professor, Department of Oral and Maxillofacial Surgery, Ankara Yildirim Beyazıt University) — Principal investigator
First posted
Aug 27, 2026
Start date
Dec 15, 2023
Primary completion
Apr 15, 2024
Completion
Dec 8, 2025
Last update
Aug 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion